<p>NeuroPace（纳斯达克代码：NPCE - 获取免费报告）在周三发布的报告中，摩根大通将其目标价格从 18.00 美元上调至 20.00 美元，Benzinga 报道。该券商目前对该股票给予 “增持” 评级。摩根大通的目标价格暗示该股票当前价格有 20.96% 的上涨潜力。</p>
<p>其他几位股票研究分析师也最近对 NPCE 发表了评论。Leerink Partners 在 11 月 5 日的研究报告中重申了对 NeuroPace 的 “跑赢大盘” 评级，并给出了 19.00 美元的目标价格。Zacks Research 在 8 月 13 日的报告中将 NeuroPace 的股票评级从 “强力买入” 下调至 “持有”。瑞银集团在周二的报告中重申了 “买入” 评级，并给出了 18.00 美元的目标价格。富国银行在 11 月 5 日的报告中将 NeuroPace 的目标价格从 15.00 美元上调至 16.00 美元，并给予该公司 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 NeuroPace 的 “卖出（d-）” 评级。六位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 17.83 美元。</p>
<p><strong>阅读我们关于 NeuroPace 的最新研究报告</strong></p>
<h2>NeuroPace 股票上涨 1.6%</h2>
<p>周三中午交易时，纳斯达克 NPCE 的股票上涨了 0.27 美元，达到 16.54 美元。该公司的交易量为 43,414 股，而其平均交易量为 250,078 股。该公司的债务与股本比率为 3.17，速动比率为 3.94，流动比率为 4.86。该公司的市值为 5.5078 亿美元，市盈率为-21.72，贝塔值为 1.85。该股票的 50 日移动平均线为 12.63 美元，200 日移动平均线为 11.04 美元。NeuroPace 的 12 个月低点为 7.56 美元，12 个月高点为 18.98 美元。</p>
<p>NeuroPace（纳斯达克代码：NPCE - 获取免费报告）在 11 月 4 日星期二发布了其财报。该公司报告本季度每股收益（EPS）为-0.11 美元，超过分析师共识预期的-0.20 美元，超出 0.09 美元。NeuroPace 的净利润率为-25.28%，股本回报率为-136.60%。该公司本季度的收入为 2735 万美元，而共识预期为 2464 万美元。作为一个整体，股票研究分析师预计 NeuroPace 在当前年度将发布-1 的每股收益。</p>
<h2>机构投资者对 NeuroPace 的看法</h2>
<p>一些机构投资者最近增加或减少了对 NPCE 的持股。Ameritas Investment Partners Inc.在第二季度将其在 NeuroPace 的持股增加了 83.6%。Ameritas Investment Partners Inc.目前拥有 2455 股该公司的股票，价值 27,000 美元，此前在上个季度增持了 1118 股。Legal &amp; General Group Plc 在第二季度将其在 NeuroPace 的持股增加了 86.0%。Legal &amp; General Group Plc 目前拥有 2679 股该公司的股票，价值 30,000 美元，此前在上个季度增持了 1239 股。GSA Capital Partners LLP 在第三季度将其在 NeuroPace 的持股增加了 2.5%。GSA Capital Partners LLP 目前拥有 54536 股该公司的股票，价值 562,000 美元，此前在上个季度增持了 1323 股。Quarry LP 在第三季度将其在 NeuroPace 的持股增加了 94.9%。Quarry LP 目前拥有 3845 股该公司的股票，价值 40,000 美元，此前在上个季度增持了 1872 股。最后，Rhumbline Advisers 在第一季度将其在 NeuroPace 的持股增加了 15.2%。Rhumbline Advisers 目前拥有 17227 股该公司的股票，价值 212,000 美元，此前在上个季度增持了 2267 股。78.83% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 NeuroPace</h2>
<p>（获取免费报告）</p>
<p>NeuroPace, Inc.是一家在美国运营的医疗设备公司。该公司开发了 RNS 系统，这是一种脑响应神经调节系统，能够在癫痫发作源头提供个性化的实时治疗，以治疗医学难治性局灶性癫痫。它还记录连续的脑活动数据，使临床医生能够面对面和远程监测患者。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 NeuroPace 更好</li>
<li>初学者如何阅读股票图表</li>
<li>苹果股票可能因创纪录的 iPhone 销售和大胆的 AI 战略而飙升</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>股息增长正在升温：三只股息稳定增长的股票</li>
<li>为什么股票行业对成功投资如此重要？</li>
<li>为什么 AutoZone 的股票下跌可能是一个绝佳的购买机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlBDRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlBDRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 NeuroPace 吗？</h2>
<p>在考虑 NeuroPace 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 NeuroPace 并不在名单上。</p>
<p>虽然 NeuroPace 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

NPCE

摩根大通

<p>摩根大通将 NeuroPace 的目标股价从 18.00 美元上调至 20.00 美元，维持 “增持” 评级，暗示有 20.96% 的上涨空间。其他分析师的评级则各有不同，普遍共识为 “适度买入”，目标股价为 17.83 美元。NeuroPace 的股票上涨 1.6%，报 16.54 美元，市值为 5.5078 亿美元。机构投资者正在积极调整在该公司的持股</p>

<p>NeuroPace (NASDAQ:NPCE - Get Free Report) had its price objective lifted by JPMorgan Chase &amp; Co. from $18.00 to $20.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target suggests a potential upside of 20.96% from the stock's current price.</p>
<div class="lb-trans"><p>NeuroPace（纳斯达克代码：NPCE - 获取免费报告）在周三发布的报告中，摩根大通将其目标价格从 18.00 美元上调至 20.00 美元，Benzinga 报道。该券商目前对该股票给予 “增持” 评级。摩根大通的目标价格暗示该股票当前价格有 20.96% 的上涨潜力。</p>
</div><p>Several other equities research analysts have also recently commented on NPCE. Leerink Partners reissued an &#34;outperform&#34; rating and issued a $19.00 price target on shares of NeuroPace in a research note on Wednesday, November 5th. Zacks Research downgraded shares of NeuroPace from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, August 13th. UBS Group reiterated a &#34;buy&#34; rating and issued a $18.00 price objective on shares of NeuroPace in a report on Tuesday. Wells Fargo &amp; Company raised their target price on NeuroPace from $15.00 to $16.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of NeuroPace in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $17.83.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也最近对 NPCE 发表了评论。Leerink Partners 在 11 月 5 日的研究报告中重申了对 NeuroPace 的 “跑赢大盘” 评级，并给出了 19.00 美元的目标价格。Zacks Research 在 8 月 13 日的报告中将 NeuroPace 的股票评级从 “强力买入” 下调至 “持有”。瑞银集团在周二的报告中重申了 “买入” 评级，并给出了 18.00 美元的目标价格。富国银行在 11 月 5 日的报告中将 NeuroPace 的目标价格从 15.00 美元上调至 16.00 美元，并给予该公司 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 NeuroPace 的 “卖出（d-）” 评级。六位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 17.83 美元。</p>
</div><p><strong>Read Our Latest Research Report on NeuroPace</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 NeuroPace 的最新研究报告</strong></p>
</div><h2>NeuroPace Stock Up 1.6%</h2>
<div class="lb-trans"><h2>NeuroPace 股票上涨 1.6%</h2>
</div><p>Shares of NASDAQ NPCE traded up $0.27 during mid-day trading on Wednesday, reaching $16.54. The company had a trading volume of 43,414 shares, compared to its average volume of 250,078. The company has a debt-to-equity ratio of 3.17, a quick ratio of 3.94 and a current ratio of 4.86. The company has a market capitalization of $550.78 million, a price-to-earnings ratio of -21.72 and a beta of 1.85. The stock has a fifty day moving average of $12.63 and a two-hundred day moving average of $11.04. NeuroPace has a 12-month low of $7.56 and a 12-month high of $18.98.</p>
<div class="lb-trans"><p>周三中午交易时，纳斯达克 NPCE 的股票上涨了 0.27 美元，达到 16.54 美元。该公司的交易量为 43,414 股，而其平均交易量为 250,078 股。该公司的债务与股本比率为 3.17，速动比率为 3.94，流动比率为 4.86。该公司的市值为 5.5078 亿美元，市盈率为-21.72，贝塔值为 1.85。该股票的 50 日移动平均线为 12.63 美元，200 日移动平均线为 11.04 美元。NeuroPace 的 12 个月低点为 7.56 美元，12 个月高点为 18.98 美元。</p>
</div><p>NeuroPace (NASDAQ:NPCE - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%. The company had revenue of $27.35 million during the quarter, compared to the consensus estimate of $24.64 million. As a group, equities research analysts expect that NeuroPace will post -1 EPS for the current year.</p>
<div class="lb-trans"><p>NeuroPace（纳斯达克代码：NPCE - 获取免费报告）在 11 月 4 日星期二发布了其财报。该公司报告本季度每股收益（EPS）为-0.11 美元，超过分析师共识预期的-0.20 美元，超出 0.09 美元。NeuroPace 的净利润率为-25.28%，股本回报率为-136.60%。该公司本季度的收入为 2735 万美元，而共识预期为 2464 万美元。作为一个整体，股票研究分析师预计 NeuroPace 在当前年度将发布-1 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On NeuroPace</h2>
<div class="lb-trans"><h2>机构投资者对 NeuroPace 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in NPCE. Ameritas Investment Partners Inc. raised its stake in NeuroPace by 83.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock worth $27,000 after acquiring an additional 1,118 shares in the last quarter. Legal &amp; General Group Plc increased its holdings in NeuroPace by 86.0% during the 2nd quarter. Legal &amp; General Group Plc now owns 2,679 shares of the company's stock valued at $30,000 after purchasing an additional 1,239 shares in the last quarter. GSA Capital Partners LLP boosted its stake in NeuroPace by 2.5% in the third quarter. GSA Capital Partners LLP now owns 54,536 shares of the company's stock worth $562,000 after purchasing an additional 1,323 shares in the last quarter. Quarry LP grew its holdings in shares of NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company's stock worth $40,000 after purchasing an additional 1,872 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of NeuroPace by 15.2% in the first quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock valued at $212,000 after buying an additional 2,267 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对 NPCE 的持股。Ameritas Investment Partners Inc.在第二季度将其在 NeuroPace 的持股增加了 83.6%。Ameritas Investment Partners Inc.目前拥有 2455 股该公司的股票，价值 27,000 美元，此前在上个季度增持了 1118 股。Legal &amp; General Group Plc 在第二季度将其在 NeuroPace 的持股增加了 86.0%。Legal &amp; General Group Plc 目前拥有 2679 股该公司的股票，价值 30,000 美元，此前在上个季度增持了 1239 股。GSA Capital Partners LLP 在第三季度将其在 NeuroPace 的持股增加了 2.5%。GSA Capital Partners LLP 目前拥有 54536 股该公司的股票，价值 562,000 美元，此前在上个季度增持了 1323 股。Quarry LP 在第三季度将其在 NeuroPace 的持股增加了 94.9%。Quarry LP 目前拥有 3845 股该公司的股票，价值 40,000 美元，此前在上个季度增持了 1872 股。最后，Rhumbline Advisers 在第一季度将其在 NeuroPace 的持股增加了 15.2%。Rhumbline Advisers 目前拥有 17227 股该公司的股票，价值 212,000 美元，此前在上个季度增持了 2267 股。78.83% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About NeuroPace</h2>
<div class="lb-trans"><h2>关于 NeuroPace</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.</p>
<div class="lb-trans"><p>NeuroPace, Inc.是一家在美国运营的医疗设备公司。该公司开发了 RNS 系统，这是一种脑响应神经调节系统，能够在癫痫发作源头提供个性化的实时治疗，以治疗医学难治性局灶性癫痫。它还记录连续的脑活动数据，使临床医生能够面对面和远程监测患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than NeuroPace</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Apple Stock Could Surge on Record iPhone Sales and Bold AI Strategy</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Dividend Growth Is Heating Up: 3 Stocks With Steady Payout Gains</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Why AutoZone’s Stock Drop Could Be a Golden Buying Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 NeuroPace 更好</li>
<li>初学者如何阅读股票图表</li>
<li>苹果股票可能因创纪录的 iPhone 销售和大胆的 AI 战略而飙升</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>股息增长正在升温：三只股息稳定增长的股票</li>
<li>为什么股票行业对成功投资如此重要？</li>
<li>为什么 AutoZone 的股票下跌可能是一个绝佳的购买机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlBDRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NPCE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in NeuroPace Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 NeuroPace 吗？</h2>
</div><p>Before you consider NeuroPace, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 NeuroPace 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 NeuroPace 并不在名单上。</p>
</div><p>While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 NeuroPace 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

摩根大通对 NeuroPace（NASDAQ:NPCE）股票价格发布了乐观的预测